The Future of Overactive Bladder Treatment Market In Healthcare Sector
Posted by Sanyukta K on August 12th, 2022
Increase in number of mergers and acquisitions is anticipated to help the industry boost in the coming years. For instance, in March 2018, Laborie had entered into a 9 million deal to buy Cogentix Medical. The takeover will give Laborie control of devices for treatment of overactive bladder (OAB) and stress urinary incontinence (SUI). Cogentix built its business around a urology portfolio spearheaded by a neuromodulation device to treat overactive bladder and a soft-tissue bulking agent for managing stress urinary incontinence.
Key Segment Covered:
Growth in number of product launches is expected to help the industry flourish during the forecast period. For instance, the FDA approved cefiderocol (FETROJA) in patients of 18 years of age or older who have limited or no alternative treatment options, for complicated urinary tract infections (cUTI), including pyelonephritis, caused by susceptible Gram-negative microorganisms such as Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Pseudomonas aeruginosa, and Enterobacter cloacae complex.
Explore More Insights@ https://www.alliedmarketresearch.com/request-toc-and-sample/10908
Major factors affecting the industry include urinary incontinence and aging in women. Moreover, increase in the number of product launches and approvals for generics is expected to fuel the market growth. Various major companies focus on leveraging strategic alliances such as expanding into multiple sectors, which are more sensitive to driving the industry.
Leading market Players:
Like it? Share it!
About the AuthorSanyukta K
Joined: July 13th, 2022
Articles Posted: 49
More by this author